Neko Health Raises $700M Series C at $7B Valuation for AI-Powered Body Scanning
The AMW Read
Incremental capital raise for an established player in an established segment; sub-§500M rounds are routine but $700M is unusually large for health AI, lifting significance to segment-level.
Neko Health Raises $700M Series C at $7B Valuation for AI-Powered Body Scanning
Swedish health-tech startup Neko Health, co-founded by a Spotify veteran, has raised $700 million in a Series C round led by Lightspeed Venture Partners, with co-lead O.G. Venture Partners and participation from existing investors Atomico, General Catalyst, and Lakestar. Axios reports the round values the company at approximately $7 billion. The company previously raised $260 million in a Series B in January 2025. Neko Health combines proprietary body-scanning hardware—featuring over 70 sensors collecting 50 million-plus data points per scan—with AI analysis and physician review to deliver comprehensive health assessments covering skin, heart, metabolism, and body composition in about one hour.
Why it matters: This $700M round, landing roughly a year after a $260M Series B, marks a sharp acceleration in capital deployment within the AI-enabled healthcare segment. Neko Health sits at the intersection of multimodal sensor hardware and AI-driven diagnostics, exemplifying the 'scanner-as-platform' model where recurring data generates both a clinical and a longitudinal AI training moat. The company's 100,000 scans completed and 350,000-person waitlist suggest strong product-market fit in a traditionally slow-moving regulatory space. The planned U.S. expansion will test whether this model can scale beyond its Swedish and British beachheads.
Grounded expert take: This raise signals that investors are betting on integrated hardware-software health platforms as the next frontier of consumer-scale preventative medicine, rather than pure-play software diagnostics. The funding intensity—nearly $1 billion in 18 months—places Neko Health among the best-capitalized health AI startups globally, alongside companies like Tempus and Viz.ai. However, the $7B valuation implies strong expectations for U.S. reimbursement dynamics and clinic adoption, which remain unproven at scale.
#NekoHealth #AIHealthcare #BodyScanning #PreventativeMedicine #HealthTech #SeriesC